Part 1: How Digital Platforms Drive Long-Term GLP-1 Success

Few medicines have driven consumer demand like GLP-1s, with people asking their doctors for them by name. Yet the path from prescription to lasting health remains fragmented. Coverage hurdles, unclear costs, and disconnected care create friction along the way, contributing to almost half of people stopping treatment within the first year. This session follows the GLP-1 care journey to pinpoint where people fall through the gaps and how consumer-driven models are closing them. Leaders in direct-to-consumer access and virtual obesity medicine will explore how connected care pathways bring together clinical support, convenient access, and cost transparency to meet people where they are. Why has healthcare lagged other industries in becoming convenient, and what is finally changing? What needs to change to ensure these models keep people connected to their care teams over time? And where must digital access hand off to the providers, pharmacies, and community supports that sustain care locally?